SCHECHTER JONATHAN

Director Schechter buys 60,000 shares of PMCB in 3 tranches (Jan 5–7) at $0.78–$0.84, raising stake 45.3% to 192,500 shares amid stock at -54.1% from 52-week high

Jonathan Schechter, Director at PharmaCyte Biotech, purchased 60,000 shares (60.0K shares) across 3 separate transactions on January 5–7, 2026 at prices of $0.78, $0.79, and $0.84, for a blended average price of $0.80 and total investment of $48,232.00 ($48.2K). His holdings rose 45.3% from 132,500 shares to 192,500 shares post-transaction. This buy occurs as the stock trades at -54.1% from its 52-week high of $1.81, with a 30-day decline of -27.8%. However, context is important: Schechter's prior cross-ticker track record shows 3 prior buys with an average 90-day return of -31.8% and a 0.00% win rate over 90 days, suggesting that his historical purchasing decisions have not coincided with price appreciation. The company fundamentals are stressed, with zero revenue in the latest quarter and a net loss of $-7,417,975.00 ($-7.4M), reflected in a market cap of only $8,411,352.80 ($8.4M).

Director Jonathan Schechter buys 10,000 shares of OBLG at $1.91; stock down 65.0% from 52-week high amid revenue decline and persistent losses.

Jonathan Schechter, a director of Oblong, Inc., purchased 10,000 shares (increasing his holdings by 66.7% to 25,000 shares total) at $1.91 on 2025-11-14 while the stock trades at $1.86, down 65.0% from its 52-week high and off 34.3% over 30 days. The company's fundamentals show severe strain: revenue declined 37.6% year-over-year to $601.0K in the latest quarter, the firm posted a net loss of $2.3M and remains unprofitable on a full-year basis, with a market cap of only $6.0M. Schechter's two prior purchases at this ticker posted a 5.0% 30-day return and a -2.6% 30-day return respectively, neither yet measurable at 90 days. His cross-ticker track record averaged +1.2% returns over 30 days on 2 buys, with no prior trades well-timed at the 90-day mark, and no timing pattern established. The purchase reflects activity by a single insider in a distressed-stage microcap with deteriorating revenue and ongoing losses.

Director Jonathan Schechter buys 5,000 OBLG shares at $2.70; stock down 58.9% from 52-week high, company unprofitable with -37.6% revenue decline

Jonathan Schechter purchased 5,000 shares at $2.70 on 2025-09-17, increasing his holdings from 10,000 to 15,000 shares. This purchase occurred as the stock trades 58.9% below its 52-week high of $6.54 and reflects a 30-day decline of -21.1%. The company faces significant headwinds: Oblong reported $592,000 in quarterly revenue with a $-605,000 net loss, alongside an annual revenue decline of -37.6% versus the prior year, leaving the company unprofitable. Schechter made a similar purchase the prior trading day (2025-09-16), suggesting back-to-back accumulation at depressed levels. However, his prior open-market trade history (1 prior cross-ticker buy) does not yet establish a pattern of well-timed acquisitions, and the lack of measurable outcomes from prior same-ticker trades limits the signal strength of this activity.

Director SCHECHTER JONATHAN buys 10,000 shares (10.0K) of OBLG at $2.73; stock down 40.1% in 90 days, -37.6% revenue growth YoY.

SCHECHTER JONATHAN purchased 10,000 shares at $2.73 on 2025-09-16 with zero prior holdings, establishing a new position. The timing occurs against a backdrop of significant deterioration: the stock has declined 40.1% over the past 90 days and trades 63.5% below its 52-week high of $6.54, while the company reported annual revenue growth of -37.6% and net income of $-605,000.00 in its latest quarter. The company's market cap of $5,617,233.73 reflects a micro-cap with negative profitability and declining top-line momentum. This purchase represents the director's first accumulation in the stock and occurs during a pronounced downtrend, though the FACTS section provides no information about the director's prior transaction history, strategic rationale, or acquisition plans that would clarify whether this reflects opportunistic entry or signaling of underlying value recognition.